Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-8gtf8 Total loading time: 0 Render date: 2025-02-23T12:51:18.015Z Has data issue: false hasContentIssue false

Rivastigmine

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Rivastigmine ([3-[(1S)-1-(dimethylamino)ethyl]phenyl]N-ethyl-N-methylcarbamate) can be found as an off-white to slightly yellow powder in oral formulations or a viscous, clear, and colourless to yellow to very slightly brown liquid in transdermal formulations. It has a molecular weight of 250.34 (as the base) and an empirical formula of C14H22N2O2.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 398 - 410
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Burn, D, Emre, M, McKeith, I, De Deyn, PP, Aarsland, D, Hsu, C, Lane, R. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21(11): 1899–1907.CrossRefGoogle ScholarPubMed
Devos, D, Moreau, C, Maltête, D, Lefaucheur, R, Kreisler, A, Eusebio, A, Defer, G, Ouk, T, Azulay, JP, Krystkowiak, P, Witjas, T, Dalliaux, M, Destée, A, Duhamel, A, Bordt, R, Defebvre, L, Dujardin, K. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014; 85(6): 668–674.CrossRefGoogle ScholarPubMed
Di Giacopo, R, Fasano, A, Quaranta, D, Della Marca, G, Bove, F, Bentiglio, AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord 2012; 27(4): 559–561.CrossRefGoogle ScholarPubMed
Emre, M, Poewe, W, De Deyn, PP, Barone, P, Kulisevsky, J, Pourcher, E, van Laar, T, Storch, A, Micheli, F, Burn, D, Durif, F, Pahwa, R, Callegari, F, Tenenbaum, N, Strohmaier, C. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol 2014; 37(1): 9–16.CrossRefGoogle ScholarPubMed
Henderson, EJ, Lord, SR, Brodie, MA, Gaunt, DM, Lawrence, AD, Close, JCT, Whone, AL, Ben-Shlomo, Y. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15(3): 249–258.CrossRefGoogle ScholarPubMed
Mamikonyan, E, Xie, SX, Melvin, E, Weintraub, D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord 2015; 30(7): 912–918.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 22 June 2022 via www.medicinescomplete.com.Google Scholar
Battle, CE, Abdul-Rassim, AH, Shenkin, SD, Hewitt, J, Quinn, TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev 2021; 2(2): CD013306.Google ScholarPubMed
Bullock, R, Cameron, A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 2002; 18(5): 258–264.CrossRefGoogle ScholarPubMed
Espay, AJ, Marsili, L, Mahajan, A, Sturchio, A, Pathan, R, Elango, DS, Pezous, N, Masellis, M, Gomez-Mancilla, B. Rivastigmine in Parkinson’s disease dementia with orthostatic hypotension. Ann Neurol 2021; 89(1): 91–98.CrossRefGoogle ScholarPubMed
Jann, MW, Shirley, KL, Small, GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–739.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 22 June 2022 via www.medicinescomplete.com.Google Scholar
Matsunaga, S, Fujishiro, H, Takechi, H. Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis 2019: 71(2): 513–523.CrossRefGoogle ScholarPubMed
McDonald, J, Pourcher, E, Nadeau, A, Corbeil, P. A randomized trial of oral and transdermal rivastigmine for postural instability in Parkinson disease dementia. Clin Neuropharmacol 2018; 41(3): 87–93.CrossRefGoogle ScholarPubMed
Rivastigmine. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 22 June 2022 via www.medicinescomplete.com.Google Scholar
Rivastigmine. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 22 June 2022 via www.micromedexsolutions.com.Google Scholar
Ruangritchankul, S, Chantharit, P, Srisuma, S, Gray, LC. Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. Ther Clin Risk Manag 2021; 17: 927–949.CrossRefGoogle ScholarPubMed
Summary of product characteristics – Nimvastid 3 mg hard capsules. Krka UK Ltd – Electronic Medicines Compendium: Nimvastid 3 mg hard capsules – summary of product characteristics (SmPC) – (emc). Accessed on 22 June 2022 via www.medicines.org.uk.Google Scholar
Yan, J, Liu, A, Huang, J, Wu, J, Shen, R, Ma, H, Yang, J. Pharmacological interventions for REM sleep behavior disorder in Parkinson’s disease: a systematic review. Front Aging Neurosci 2021. 13: 709878.CrossRefGoogle ScholarPubMed
Youn, YC, Shin, HW, Choi, BS, Kim, SY, Lee, JY, Ha, YC. Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. Int J Geriatr Psychiatry 2017; 32(10): 1079–1084.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Rivastigmine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.042
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Rivastigmine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.042
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Rivastigmine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.042
Available formats
×